# US 2019/0314523 A1 · Tumor-targeting synthetic adenoviruses and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0314523 A1
- Document ID: US20190314523A1
- Status: Published application
- Kind: A1
- Application number: 16/434,714
- Filed: 2019-06-07
- Published: 2019-10-17
- Earliest claimed: 2016-12-12
- Assignees: The Salk Institute for Biological Studies
- Applicants: Salk Institute for Biological Studies
- Inventors: Clodagh O'Shea; Colin Powers; Lei Zhang
- Web page: https://patentgrep.com/patent/US20190314523A1

## CPC

- A61K 48/005: {characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered}
- A61P 35/00: Antineoplastic agents
- C07K 14/005: from viruses
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C12N 15/86: Viral vectors
- C12Q 1/66: involving luciferase
- A01K 2207/12: Animals modified by administration of exogenous cells
- A01K 2217/075: inducing loss of function, i.e. knock out
- A01K 2217/077: heterozygous knock out animals displaying phenotype
- A01K 2227/105: Murine
- A01K 2267/0331: Animal model for proliferative diseases
- C12N 2710/10322: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2710/10332: Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- C12N 2710/10343: viral genome or elements thereof as genetic vector
- C12N 2710/10345: Special targeting system for viral vectors
- C12N 2799/022: where the vector is derived from an adenovirus
- C12Y 113/12007: Photinus-luciferin 4-monooxygenase (ATP-hydrolysing) (1.13.12.7), i.e. firefly-luciferase
- G01N 2800/7028: Cancer
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- C12Y: ENZYMES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Synthetic adenoviruses with liver detargeting mutations and expressing an adenovirus type 34 (Ad34) fiber protein, or a chimeric fiber protein with an Ad34 knob domain, are described. The synthetic adenoviruses traffic to sites of tumors. Use of the synthetic adenoviruses for delivering diagnostic or therapeutic transgenes to tumors are also described.

## Claims

### Claim 1

A method of expressing a transgene in tumor cells of a subject, comprising administering to the subject a synthetic adenovirus comprising:
the transgene;
a native or modified capsid that detargets the synthetic adenovirus from the liver; and
an adenovirus type 34 (Ad34) fiber protein or a chimeric fiber protein comprising an adenovirus type 5 (Ad5) shaft domain and an Ad34 knob domain.

### Claim 2 (depends on 1)

The method of claim 1, wherein the transgene is a diagnostic transgene or a therapeutic transgene.

### Claim 3 (depends on 2)

The method of claim 2, wherein the diagnostic transgene encodes a fluorescent protein, encodes an enzyme, or comprises a positron emission tomography (PET) reporter gene.

### Claim 4 (depends on 2)

The method of claim 2, wherein the therapeutic transgene encodes an anti-cancer agent, or an agent that disrupts or kills tumor stromal cells.

### Claim 5

A method of diagnosing a subject as having a tumor, comprising administering to the subject a synthetic adenovirus comprising:
a diagnostic transgene;
a native or modified capsid that detargets the synthetic adenovirus from the liver; and
an adenovirus type 34 (Ad34) fiber protein or a chimeric fiber protein comprising an adenovirus type 5 (Ad5) shaft domain and an Ad34 knob domain.

### Claim 6 (depends on 5)

The method of claim 5, wherein the diagnostic transgene comprises a positron emission tomography (PET) reporter gene, encodes a fluorescent protein or encodes an enzyme.

### Claim 7 (depends on 6)

The method of claim 6, wherein the fluorescent protein comprises a green fluorescent protein (GFP), a yellow fluorescent protein (YFP), a cyan fluorescent protein (CFP), a red fluorescent protein (RFP), a blue fluorescent protein (BFP), or an orange fluorescent protein.

### Claim 8 (depends on 6)

The method of claim 6, wherein the enzyme is a luciferase.

### Claim 9

A method of treating a tumor in a subject, comprising administering to the subject a synthetic adenovirus comprising:
a therapeutic transgene;
a native or modified capsid that detargets the synthetic adenovirus from the liver; and
an adenovirus type 34 (Ad34) fiber protein or a chimeric fiber protein comprising an adenovirus type 5 (Ad5) shaft domain and an Ad34 knob domain.

### Claim 10 (depends on 9)

The method of claim 9, wherein the therapeutic transgene encodes an anti-cancer agent or an agent that disrupts or kills tumor stromal cells.

### Claim 11 (depends on 1)

The method of claim 1, wherein the synthetic adenovirus comprises a modified capsid that detargets the synthetic adenovirus from the liver.

### Claim 12 (depends on 1)

The method of claim 1, wherein the synthetic adenovirus further comprises one or more binding sites for a liver-specific microRNA.

### Claim 13 (depends on 12)

The method of claim 12, wherein the liver-specific microRNA is miR-122.

### Claim 14 (depends on 1)

The method of claim 1, wherein the synthetic adenovirus further comprises one or more binding sites for a spleen-specific microRNA.

### Claim 15 (depends on 14)

The method of claim 14, wherein the spleen-specific microRNA is miR142-3p.

### Claim 16 (depends on 1)

The method of claim 1, wherein expression of the transgene is regulated by a tissue-specific promoter.

### Claim 17 (depends on 1)

The method of claim 1, wherein the synthetic adenovirus comprises Ad5 capsid proteins and a chimeric fiber protein comprising an Ad5 shaft domain and an Ad34 knob domain.

### Claim 18 (depends on 1)

The method of claim 1, wherein the tumor is a pancreatic tumor or a glioblastoma.

### Claim 19

A synthetic adenovirus genome, comprising a nucleotide sequence at least 95% identical to SEQ ID NO: 2 or SEQ ID NO: 5.

### Claim 20 (depends on 19)

The synthetic adenovirus genome of claim 19, comprising SEQ ID NO: 2 or SEQ ID NO: 5.
